The Market Reports
Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com
Heart Failure Therapeutics-Global Market Insights and Sales Trends 2024
Synopsis
Heart failure (HF), often referred to as congestive heart failure (CHF), is when the heart is unable to pump sufficiently to maintain blood flow to meet the body's needs. Signs and symptoms commonly include shortness of breath, excessive tiredness, and leg swelling.The shortness of breath is usually worse with exercise, while lying down, and may wake the person at night.A limited ability to exercise is also a common feature. Chest pain, including angina, does not typically occur due to heart failure.
The global Heart Failure Therapeutics market size is expected to reach US$ million by 2029, growing at a CAGR of % from 2023 to 2029. The market is mainly driven by the significant applications of Heart Failure Therapeutics in various end use industries. The expanding demands from the Hospital, Clinic and Medical Research Organization,, are propelling Heart Failure Therapeutics market. Diagnosis, one of the segments analysed in this report, is projected to record % CAGR and reach US$ million by the end of the analysis period. Growth in the Prognosis segment is estimated at % CAGR for the next seven-year period.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
Report Objectives
This report provides market insight on the different segments, by players, by Type, by Application. Market size and forecast (2018-2029) has been provided in the report. The primary objectives of this report are to provide 1) global market size and forecasts, growth rates, market dynamics, industry structure and developments, market situation, trends; 2) global market share and ranking by company; 3) comprehensive presentation of the global market for Heart Failure Therapeutics, with both quantitative and qualitative analysis through detailed segmentation; 4) detailed value chain analysis and review of growth factors essential for the existing market players and new entrants; 5) emerging opportunities in the market and the future impact of major drivers and restraints of the market.
Key Features of The Study:
This report provides in-depth analysis of the global Heart Failure Therapeutics market, and provides market size (US$ million) and CAGR for the forecast period (2023-2029), considering 2022 as the base year.
This report profiles key players in the global Heart Failure Therapeutics market based on the following parameters - company details (found date, headquarters, manufacturing bases), products portfolio, Heart Failure Therapeutics sales data, market share and ranking.
This report elucidates potential market opportunities across different segments and explains attractive investment proposition matrices for this market.
This report illustrates key insights about market drivers, restraints, opportunities, market trends, regional outlook.
Key companies of Heart Failure Therapeutics covered in this report include Bayer, Cynokinetics, Les Laboratoires Servier, Merck & Co., Novartis, Procoralan, Bristol-Myers Squibb Company, Cardiorentis AG and CVie Therapeutics Limited, etc.
The global Heart Failure Therapeutics market report caters to various stakeholders in this industry including investors, suppliers, product players, distributors, new entrants, and financial analysts.
Market Segmentation
Company Profiles:
Bayer
Cynokinetics
Les Laboratoires Servier
Merck & Co.
Novartis
Procoralan
Bristol-Myers Squibb Company
Cardiorentis AG
CVie Therapeutics Limited
Orion Corporation
PhaseBio Pharmaceuticals
Market Segment by Product Type
B-Blockers
Calcium Channel Blockers
Cardiac Glycosides
Diuretics
Morphine
Vasodilators/Nitrates
Global Heart Failure Therapeutics market, by region:
North America (U.S., Canada, Mexico)
Europe (Germany, France, UK, Italy, etc.)
Asia Pacific (China, Japan, South Korea, Southeast Asia, India, etc.)
South America (Brazil, etc.)
Middle East and Africa (Turkey, GCC Countries, Africa, etc.)
Global Heart Failure Therapeutics market, Segment by Type:
Diagnosis
Prognosis
Treatment Options and Treatment Algorithm
Global Heart Failure Therapeutics market, by Application
Hospital
Clinic
Medical Research Organization
Core Chapters
Chapter One: Introduces the report scope of the report, executive summary of global and regional market size and CAGR for the history and forecast period (2018-2023, 2024-2029). It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter Two: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter Three: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter Four: Detailed analysis of Heart Failure Therapeutics companies’ competitive landscape, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.
Chapter Five: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product introduction, revenue, recent development, etc.
Chapter Six, Seven, Eight, Nine and Ten: North America, Europe, Asia Pacific, Latin America, Middle East & Africa, revenue by country.
Chapter Eleven: this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter Twelve: Research Finding/Conclusion
Heart failure (HF), often referred to as congestive heart failure (CHF), is when the heart is unable to pump sufficiently to maintain blood flow to meet the body's needs. Signs and symptoms commonly include shortness of breath, excessive tiredness, and leg swelling.The shortness of breath is usually worse with exercise, while lying down, and may wake the person at night.A limited ability to exercise is also a common feature. Chest pain, including angina, does not typically occur due to heart failure.
The global Heart Failure Therapeutics market size is expected to reach US$ million by 2029, growing at a CAGR of % from 2023 to 2029. The market is mainly driven by the significant applications of Heart Failure Therapeutics in various end use industries. The expanding demands from the Hospital, Clinic and Medical Research Organization,, are propelling Heart Failure Therapeutics market. Diagnosis, one of the segments analysed in this report, is projected to record % CAGR and reach US$ million by the end of the analysis period. Growth in the Prognosis segment is estimated at % CAGR for the next seven-year period.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
Report Objectives
This report provides market insight on the different segments, by players, by Type, by Application. Market size and forecast (2018-2029) has been provided in the report. The primary objectives of this report are to provide 1) global market size and forecasts, growth rates, market dynamics, industry structure and developments, market situation, trends; 2) global market share and ranking by company; 3) comprehensive presentation of the global market for Heart Failure Therapeutics, with both quantitative and qualitative analysis through detailed segmentation; 4) detailed value chain analysis and review of growth factors essential for the existing market players and new entrants; 5) emerging opportunities in the market and the future impact of major drivers and restraints of the market.
Key Features of The Study:
This report provides in-depth analysis of the global Heart Failure Therapeutics market, and provides market size (US$ million) and CAGR for the forecast period (2023-2029), considering 2022 as the base year.
This report profiles key players in the global Heart Failure Therapeutics market based on the following parameters - company details (found date, headquarters, manufacturing bases), products portfolio, Heart Failure Therapeutics sales data, market share and ranking.
This report elucidates potential market opportunities across different segments and explains attractive investment proposition matrices for this market.
This report illustrates key insights about market drivers, restraints, opportunities, market trends, regional outlook.
Key companies of Heart Failure Therapeutics covered in this report include Bayer, Cynokinetics, Les Laboratoires Servier, Merck & Co., Novartis, Procoralan, Bristol-Myers Squibb Company, Cardiorentis AG and CVie Therapeutics Limited, etc.
The global Heart Failure Therapeutics market report caters to various stakeholders in this industry including investors, suppliers, product players, distributors, new entrants, and financial analysts.
Market Segmentation
Company Profiles:
Bayer
Cynokinetics
Les Laboratoires Servier
Merck & Co.
Novartis
Procoralan
Bristol-Myers Squibb Company
Cardiorentis AG
CVie Therapeutics Limited
Orion Corporation
PhaseBio Pharmaceuticals
Market Segment by Product Type
B-Blockers
Calcium Channel Blockers
Cardiac Glycosides
Diuretics
Morphine
Vasodilators/Nitrates
Global Heart Failure Therapeutics market, by region:
North America (U.S., Canada, Mexico)
Europe (Germany, France, UK, Italy, etc.)
Asia Pacific (China, Japan, South Korea, Southeast Asia, India, etc.)
South America (Brazil, etc.)
Middle East and Africa (Turkey, GCC Countries, Africa, etc.)
Global Heart Failure Therapeutics market, Segment by Type:
Diagnosis
Prognosis
Treatment Options and Treatment Algorithm
Global Heart Failure Therapeutics market, by Application
Hospital
Clinic
Medical Research Organization
Core Chapters
Chapter One: Introduces the report scope of the report, executive summary of global and regional market size and CAGR for the history and forecast period (2018-2023, 2024-2029). It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter Two: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter Three: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter Four: Detailed analysis of Heart Failure Therapeutics companies’ competitive landscape, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.
Chapter Five: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product introduction, revenue, recent development, etc.
Chapter Six, Seven, Eight, Nine and Ten: North America, Europe, Asia Pacific, Latin America, Middle East & Africa, revenue by country.
Chapter Eleven: this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter Twelve: Research Finding/Conclusion
Index1 Market Overview of Heart Failure Therapeutics
1.1 Heart Failure Therapeutics Market Overview
1.1.1 Heart Failure Therapeutics Product Scope
1.1.2 Heart Failure Therapeutics Market Status and Outlook
1.2 Global Heart Failure Therapeutics Market Size Overview by Region 2018 VS 2022 VS 2029
1.3 Global Heart Failure Therapeutics Market Size by Region (2018-2029)
1.4 Global Heart Failure Therapeutics Historic Market Size by Region (2018-2023)
1.5 Global Heart Failure Therapeutics Market Size Forecast by Region (2024-2029)
1.6 Key Regions, Heart Failure Therapeutics Market Size (2018-2029)
1.6.1 North America Heart Failure Therapeutics Market Size (2018-2029)
1.6.2 Europe Heart Failure Therapeutics Market Size (2018-2029)
1.6.3 Asia-Pacific Heart Failure Therapeutics Market Size (2018-2029)
1.6.4 Latin America Heart Failure Therapeutics Market Size (2018-2029)
1.6.5 Middle East & Africa Heart Failure Therapeutics Market Size (2018-2029)
2 Heart Failure Therapeutics Market by Type
2.1 Introduction
2.1.1 Diagnosis
2.1.2 Prognosis
2.1.3 Treatment Options and Treatment Algorithm
2.2 Global Heart Failure Therapeutics Market Size by Type: 2018 VS 2022 VS 2029
2.2.1 Global Heart Failure Therapeutics Historic Market Size by Type (2018-2023)
2.2.2 Global Heart Failure Therapeutics Forecasted Market Size by Type (2024-2029)
2.3 Key Regions Market Size by Type
2.3.1 North America Heart Failure Therapeutics Revenue Breakdown by Type (2018-2029)
2.3.2 Europe Heart Failure Therapeutics Revenue Breakdown by Type (2018-2029)
2.3.3 Asia-Pacific Heart Failure Therapeutics Revenue Breakdown by Type (2018-2029)
2.3.4 Latin America Heart Failure Therapeutics Revenue Breakdown by Type (2018-2029)
2.3.5 Middle East and Africa Heart Failure Therapeutics Revenue Breakdown by Type (2018-2029)
3 Heart Failure Therapeutics Market Overview by Application
3.1 Introduction
3.1.1 Hospital
3.1.2 Clinic
3.1.3 Medical Research Organization
3.2 Global Heart Failure Therapeutics Market Size by Application: 2018 VS 2022 VS 2029
3.2.1 Global Heart Failure Therapeutics Historic Market Size by Application (2018-2023)
3.2.2 Global Heart Failure Therapeutics Forecasted Market Size by Application (2024-2029)
3.3 Key Regions Market Size by Application
3.3.1 North America Heart Failure Therapeutics Revenue Breakdown by Application (2018-2029)
3.3.2 Europe Heart Failure Therapeutics Revenue Breakdown by Application (2018-2029)
3.3.3 Asia-Pacific Heart Failure Therapeutics Revenue Breakdown by Application (2018-2029)
3.3.4 Latin America Heart Failure Therapeutics Revenue Breakdown by Application (2018-2029)
3.3.5 Middle East and Africa Heart Failure Therapeutics Revenue Breakdown by Application (2018-2029)
4 Heart Failure Therapeutics Competition Analysis by Players
4.1 Global Heart Failure Therapeutics Market Size by Players (2018-2023)
4.2 Global Top Players by Company Type (Tier 1, Tier 2 and Tier 3) & (based on the Revenue in Heart Failure Therapeutics as of 2022)
4.3 Date of Key Players Enter into Heart Failure Therapeutics Market
4.4 Global Top Players Heart Failure Therapeutics Headquarters and Area Served
4.5 Key Players Heart Failure Therapeutics Product Solution and Service
4.6 Competitive Status
4.6.1 Heart Failure Therapeutics Market Concentration Rate
4.6.2 Mergers & Acquisitions, Expansion Plans
5 Company (Top Players) Profiles
5.1 Bayer
5.1.1 Bayer Profile
5.1.2 Bayer Main Business
5.1.3 Bayer Heart Failure Therapeutics Products, Services and Solutions
5.1.4 Bayer Heart Failure Therapeutics Revenue (US$ Million) & (2018-2023)
5.1.5 Bayer Recent Developments
5.2 Cynokinetics
5.2.1 Cynokinetics Profile
5.2.2 Cynokinetics Main Business
5.2.3 Cynokinetics Heart Failure Therapeutics Products, Services and Solutions
5.2.4 Cynokinetics Heart Failure Therapeutics Revenue (US$ Million) & (2018-2023)
5.2.5 Cynokinetics Recent Developments
5.3 Les Laboratoires Servier
5.3.1 Les Laboratoires Servier Profile
5.3.2 Les Laboratoires Servier Main Business
5.3.3 Les Laboratoires Servier Heart Failure Therapeutics Products, Services and Solutions
5.3.4 Les Laboratoires Servier Heart Failure Therapeutics Revenue (US$ Million) & (2018-2023)
5.3.5 Merck & Co. Recent Developments
5.4 Merck & Co.
5.4.1 Merck & Co. Profile
5.4.2 Merck & Co. Main Business
5.4.3 Merck & Co. Heart Failure Therapeutics Products, Services and Solutions
5.4.4 Merck & Co. Heart Failure Therapeutics Revenue (US$ Million) & (2018-2023)
5.4.5 Merck & Co. Recent Developments
5.5 Novartis
5.5.1 Novartis Profile
5.5.2 Novartis Main Business
5.5.3 Novartis Heart Failure Therapeutics Products, Services and Solutions
5.5.4 Novartis Heart Failure Therapeutics Revenue (US$ Million) & (2018-2023)
5.5.5 Novartis Recent Developments
5.6 Procoralan
5.6.1 Procoralan Profile
5.6.2 Procoralan Main Business
5.6.3 Procoralan Heart Failure Therapeutics Products, Services and Solutions
5.6.4 Procoralan Heart Failure Therapeutics Revenue (US$ Million) & (2018-2023)
5.6.5 Procoralan Recent Developments
5.7 Bristol-Myers Squibb Company
5.7.1 Bristol-Myers Squibb Company Profile
5.7.2 Bristol-Myers Squibb Company Main Business
5.7.3 Bristol-Myers Squibb Company Heart Failure Therapeutics Products, Services and Solutions
5.7.4 Bristol-Myers Squibb Company Heart Failure Therapeutics Revenue (US$ Million) & (2018-2023)
5.7.5 Bristol-Myers Squibb Company Recent Developments
5.8 Cardiorentis AG
5.8.1 Cardiorentis AG Profile
5.8.2 Cardiorentis AG Main Business
5.8.3 Cardiorentis AG Heart Failure Therapeutics Products, Services and Solutions
5.8.4 Cardiorentis AG Heart Failure Therapeutics Revenue (US$ Million) & (2018-2023)
5.8.5 Cardiorentis AG Recent Developments
5.9 CVie Therapeutics Limited
5.9.1 CVie Therapeutics Limited Profile
5.9.2 CVie Therapeutics Limited Main Business
5.9.3 CVie Therapeutics Limited Heart Failure Therapeutics Products, Services and Solutions
5.9.4 CVie Therapeutics Limited Heart Failure Therapeutics Revenue (US$ Million) & (2018-2023)
5.9.5 CVie Therapeutics Limited Recent Developments
5.10 Orion Corporation
5.10.1 Orion Corporation Profile
5.10.2 Orion Corporation Main Business
5.10.3 Orion Corporation Heart Failure Therapeutics Products, Services and Solutions
5.10.4 Orion Corporation Heart Failure Therapeutics Revenue (US$ Million) & (2018-2023)
5.10.5 Orion Corporation Recent Developments
5.11 PhaseBio Pharmaceuticals
5.11.1 PhaseBio Pharmaceuticals Profile
5.11.2 PhaseBio Pharmaceuticals Main Business
5.11.3 PhaseBio Pharmaceuticals Heart Failure Therapeutics Products, Services and Solutions
5.11.4 PhaseBio Pharmaceuticals Heart Failure Therapeutics Revenue (US$ Million) & (2018-2023)
5.11.5 PhaseBio Pharmaceuticals Recent Developments
5.12 Market Segment by Product Type
5.12.1 Market Segment by Product Type Profile
5.12.2 Market Segment by Product Type Main Business
5.12.3 Market Segment by Product Type Heart Failure Therapeutics Products, Services and Solutions
5.12.4 Market Segment by Product Type Heart Failure Therapeutics Revenue (US$ Million) & (2018-2023)
5.12.5 Market Segment by Product Type Recent Developments
5.13 B-Blockers
5.13.1 B-Blockers Profile
5.13.2 B-Blockers Main Business
5.13.3 B-Blockers Heart Failure Therapeutics Products, Services and Solutions
5.13.4 B-Blockers Heart Failure Therapeutics Revenue (US$ Million) & (2018-2023)
5.13.5 B-Blockers Recent Developments
5.14 Calcium Channel Blockers
5.14.1 Calcium Channel Blockers Profile
5.14.2 Calcium Channel Blockers Main Business
5.14.3 Calcium Channel Blockers Heart Failure Therapeutics Products, Services and Solutions
5.14.4 Calcium Channel Blockers Heart Failure Therapeutics Revenue (US$ Million) & (2018-2023)
5.14.5 Calcium Channel Blockers Recent Developments
5.15 Cardiac Glycosides
5.15.1 Cardiac Glycosides Profile
5.15.2 Cardiac Glycosides Main Business
5.15.3 Cardiac Glycosides Heart Failure Therapeutics Products, Services and Solutions
5.15.4 Cardiac Glycosides Heart Failure Therapeutics Revenue (US$ Million) & (2018-2023)
5.15.5 Cardiac Glycosides Recent Developments
5.16 Diuretics
5.16.1 Diuretics Profile
5.16.2 Diuretics Main Business
5.16.3 Diuretics Heart Failure Therapeutics Products, Services and Solutions
5.16.4 Diuretics Heart Failure Therapeutics Revenue (US$ Million) & (2018-2023)
5.16.5 Diuretics Recent Developments
5.17 Morphine
5.17.1 Morphine Profile
5.17.2 Morphine Main Business
5.17.3 Morphine Heart Failure Therapeutics Products, Services and Solutions
5.17.4 Morphine Heart Failure Therapeutics Revenue (US$ Million) & (2018-2023)
5.17.5 Morphine Recent Developments
5.18 Vasodilators/Nitrates
5.18.1 Vasodilators/Nitrates Profile
5.18.2 Vasodilators/Nitrates Main Business
5.18.3 Vasodilators/Nitrates Heart Failure Therapeutics Products, Services and Solutions
5.18.4 Vasodilators/Nitrates Heart Failure Therapeutics Revenue (US$ Million) & (2018-2023)
5.18.5 Vasodilators/Nitrates Recent Developments
6 North America
6.1 North America Heart Failure Therapeutics Market Size by Country (2018-2029)
6.2 U.S.
6.3 Canada
7 Europe
7.1 Europe Heart Failure Therapeutics Market Size by Country (2018-2029)
7.2 Germany
7.3 France
7.4 U.K.
7.5 Italy
7.6 Russia
7.7 Nordic Countries
7.8 Rest of Europe
8 Asia-Pacific
8.1 Asia-Pacific Heart Failure Therapeutics Market Size by Region (2018-2029)
8.2 China
8.3 Japan
8.4 South Korea
8.5 Southeast Asia
8.6 India
8.7 Australia
8.8 Rest of Asia-Pacific
9 Latin America
9.1 Latin America Heart Failure Therapeutics Market Size by Country (2018-2029)
9.2 Mexico
9.3 Brazil
9.4 Rest of Latin America
10 Middle East & Africa
10.1 Middle East & Africa Heart Failure Therapeutics Market Size by Country (2018-2029)
10.2 Turkey
10.3 Saudi Arabia
10.4 UAE
10.5 Rest of Middle East & Africa
11 Heart Failure Therapeutics Market Dynamics
11.1 Heart Failure Therapeutics Industry Trends
11.2 Heart Failure Therapeutics Market Drivers
11.3 Heart Failure Therapeutics Market Challenges
11.4 Heart Failure Therapeutics Market Restraints
12 Research Finding /Conclusion
13 Methodology and Data Source
13.1 Methodology/Research Approach
13.1.1 Research Programs/Design
13.1.2 Market Size Estimation
13.1.3 Market Breakdown and Data Triangulation
13.2 Data Source
13.2.1 Secondary Sources
13.2.2 Primary Sources
13.3 Disclaimer
13.4 Author List
Published By : QY Research
Why ‘The Market Reports’
In Business:
Pre Sales Support:
Post Sales Support:
Turn Around Time:
Clients Served:
Clients Assisted:
Client Types:
Payment:
- Accept global payments [Credit Card / PayPal / Wire Transfer]
- Accept local payments in South Korea, Germany, China and India [Can pay in local currency]
Latest Life Science Market Reports
Payments Accepted From
Connect with us at
Complete Secure Website
